H.C. Wainwright Reiterates Buy Rating on Collegium Pharmaceutical (COLL)

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating and $50.00 price target on Collegium Pharmaceutical (NASDAQ: COLL).

The analyst commented: "We’ve been disappointed to see the stock just trade in line with the pressured XBI. We think COLL is an underappreciated name in the current risk-off environment where we’ve seen rotation into—and outperformance from—other names generating strong cash flows or with visibility to near-term breakeven without financing needs. COLL currently trades at only 3.7x midpoint 2025 EV/EBITDA guidance, and the company has beaten initial EBITDA guidance each of the last three years. We understand why the compressed multiple, as Nucynta IR/ER and Belbuca—25% and 30% of pro forma 2024 revenue, respectively—face potential generic risk in the next 2+ years. We reiterate our Buy rating, reminding that even our Street-high $50 price target, COLL would still only trade at 5.4x EV/EBITDA."

For an analyst ratings summary and ratings history on Collegium Pharmaceutical click here. For more ratings news on Collegium Pharmaceutical click here.

Shares of Collegium Pharmaceutical closed at $30.05 yesterday.

You May Also Be Interested In

• B.Riley Starts Suncrete Inc (RMIX) at Buy
• Upstart renews $600M loan deal with Neuberger Specialty Finance
• Benchmark Reiterates Buy Rating on Saia Inc. (SAIA) Following Operating Update